Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)
|出版日期||內容資訊||英文 56 Pages
|市場焦點:注意力不足過動症(ADHD) Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)|
|出版日期: 2019年10月25日||內容資訊: 英文 56 Pages||
本報告提供ADHD (過動症)的治療藥市場相關分析，提供疾病概要和患者數的轉變·預測，目前的主要治療方法，ADHD治療藥市場趨勢預測 (今後10年份)，資本交易的動向，目前開發中的臨床實驗進展等調查。
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were 177.3 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 187.4 million prevalent cases by
2026. Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor. The vast majority of approved therapies are administered via the oral route.
The largest proportion of industry-sponsored drugs in active clinical development for ADHD are in Phase III. Therapies in mid-to-late-stage development for ADHD focus on a wide variety of targets. The majority of pipeline drugs in midto-late-stage development are administered via the oral route, with only one drug also being tested in intramuscular and subcutaneous formulations.
High-impact upcoming events for drugs in the ADHD space comprise topline Phase III trial results, pivotal efficacy study results, an expected patent expiration, and a meeting with the FDA.
The overall likelihood of approval of a Phase I ADHD asset is 12.9%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 8.8 years in the overall psychiatry space.
There have been 21 licensing and asset acquisition deals involving ADHD drugs during 2014-19. Impax Laboratories' acquisition of certain assets related to generic products from Teva and Allergan in 2016 for $586m was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ADHD have been in the late phases of development, with 54% in Phase III-IV, and 46% in Phase I-II.
The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the ADHD space is dominated by completed trials. Takeda has the highest number of completed clinical trials for ADHD, with 157 trials.
Takeda leads the industry sponsors with the highest number of clinical trials for ADHD, followed by Eli Lilly and Johnson & Johnson